A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
Conditions
Multiple Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Profound Research, LLC, Carlsbad, California, United States
Neurology Associates, PA, Maitland, Florida, United States
University of South Florida, Tampa, Florida, United States
Shepherd Center Inc., Atlanta, Georgia, United States
John Hopkins University School of Medicine, Baltimore, Maryland, United States
Hope Neurology, Knoxville, Tennessee, United States
Instituto de Neurologia de Curitiba, Curitiba, Paraná, Brazil
Centro de Pesquisas Clinicas, São Paulo, São Paulo, Brazil
Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C., Guadalajara, Jalisco, Mexico
Inovacion y Desarrollo en ciencias de la salud, Mexico City, Mexico CITY (federal District), Mexico
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
Morriston Hospital, Swansea, United Kingdom
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche